Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma

Colin Kennedy, Kim Bull, Mathilde Chevignard, David Culliford, Helmuth G. Dörr, François Doz, Rolf Dieter Kortmann, Birgitta Lannering, Maura Massimino, Aurora Navajas Gutiérrez, Stefan Rutkowski, Helen A. Spoudeas, Gabriele Calaminus

Research output: Contribution to journalArticle

Abstract

Purpose To compare quality of survival in "standard-risk" medulloblastoma after hyperfractionated radiation therapy of the central nervous system with that after standard radiation therapy, combined with a chemotherapy regimen common to both treatment arms, in the PNET4 randomised controlled trial. Methods and Materials Participants in the PNET4 trial and their parents/caregivers in 7 participating anonymized countries completed standardized questionnaires in their own language on executive function, health status, behavior, health-related quality of life, and medical, educational, employment, and social information. Pre- and postoperative neurologic status and serial heights and weights were also recorded. Results Data were provided by 151 of 244 eligible survivors (62%) at a median age at assessment of 15.2 years and median interval from diagnosis of 5.8 years. Compared with standard radiation therapy, hyperfractionated radiation therapy was associated with lower (ie, better) z-scores for executive function in all participants (mean intergroup difference 0.48 SDs, 95% confidence interval 0.16-0.81, P=.004), but health status, behavioral difficulties, and health-related quality of life z-scores were similar in the 2 treatment arms. Data on hearing impairment were equivocal. Hyperfractionated radiation therapy was also associated with greater decrement in height z-scores (mean intergroup difference 0.43 SDs, 95% confidence interval 0.10-0.76, P=.011). Conclusions Hyperfractionated radiation therapy was associated with better executive function and worse growth but without accompanying change in health status, behavior, or quality of life.

Original languageEnglish
Pages (from-to)292-300
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume88
Issue number2
DOIs
Publication statusPublished - Feb 1 2014

Fingerprint

Medulloblastoma
Young Adult
radiation therapy
Radiotherapy
health
Survival
Executive Function
Growth
Health Status
Quality of Life
intervals
confidence
Confidence Intervals
central nervous system
impairment
chemotherapy
hearing
Hearing Loss
Nervous System
Caregivers

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. / Kennedy, Colin; Bull, Kim; Chevignard, Mathilde; Culliford, David; Dörr, Helmuth G.; Doz, François; Kortmann, Rolf Dieter; Lannering, Birgitta; Massimino, Maura; Navajas Gutiérrez, Aurora; Rutkowski, Stefan; Spoudeas, Helen A.; Calaminus, Gabriele.

In: International Journal of Radiation Oncology Biology Physics, Vol. 88, No. 2, 01.02.2014, p. 292-300.

Research output: Contribution to journalArticle

Kennedy, Colin ; Bull, Kim ; Chevignard, Mathilde ; Culliford, David ; Dörr, Helmuth G. ; Doz, François ; Kortmann, Rolf Dieter ; Lannering, Birgitta ; Massimino, Maura ; Navajas Gutiérrez, Aurora ; Rutkowski, Stefan ; Spoudeas, Helen A. ; Calaminus, Gabriele. / Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. In: International Journal of Radiation Oncology Biology Physics. 2014 ; Vol. 88, No. 2. pp. 292-300.
@article{892ff9e1d18e4114aa3f493d53d6f937,
title = "Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma",
abstract = "Purpose To compare quality of survival in {"}standard-risk{"} medulloblastoma after hyperfractionated radiation therapy of the central nervous system with that after standard radiation therapy, combined with a chemotherapy regimen common to both treatment arms, in the PNET4 randomised controlled trial. Methods and Materials Participants in the PNET4 trial and their parents/caregivers in 7 participating anonymized countries completed standardized questionnaires in their own language on executive function, health status, behavior, health-related quality of life, and medical, educational, employment, and social information. Pre- and postoperative neurologic status and serial heights and weights were also recorded. Results Data were provided by 151 of 244 eligible survivors (62{\%}) at a median age at assessment of 15.2 years and median interval from diagnosis of 5.8 years. Compared with standard radiation therapy, hyperfractionated radiation therapy was associated with lower (ie, better) z-scores for executive function in all participants (mean intergroup difference 0.48 SDs, 95{\%} confidence interval 0.16-0.81, P=.004), but health status, behavioral difficulties, and health-related quality of life z-scores were similar in the 2 treatment arms. Data on hearing impairment were equivocal. Hyperfractionated radiation therapy was also associated with greater decrement in height z-scores (mean intergroup difference 0.43 SDs, 95{\%} confidence interval 0.10-0.76, P=.011). Conclusions Hyperfractionated radiation therapy was associated with better executive function and worse growth but without accompanying change in health status, behavior, or quality of life.",
author = "Colin Kennedy and Kim Bull and Mathilde Chevignard and David Culliford and D{\"o}rr, {Helmuth G.} and Fran{\cc}ois Doz and Kortmann, {Rolf Dieter} and Birgitta Lannering and Maura Massimino and {Navajas Guti{\'e}rrez}, Aurora and Stefan Rutkowski and Spoudeas, {Helen A.} and Gabriele Calaminus",
year = "2014",
month = "2",
day = "1",
doi = "10.1016/j.ijrobp.2013.09.046",
language = "English",
volume = "88",
pages = "292--300",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma

AU - Kennedy, Colin

AU - Bull, Kim

AU - Chevignard, Mathilde

AU - Culliford, David

AU - Dörr, Helmuth G.

AU - Doz, François

AU - Kortmann, Rolf Dieter

AU - Lannering, Birgitta

AU - Massimino, Maura

AU - Navajas Gutiérrez, Aurora

AU - Rutkowski, Stefan

AU - Spoudeas, Helen A.

AU - Calaminus, Gabriele

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Purpose To compare quality of survival in "standard-risk" medulloblastoma after hyperfractionated radiation therapy of the central nervous system with that after standard radiation therapy, combined with a chemotherapy regimen common to both treatment arms, in the PNET4 randomised controlled trial. Methods and Materials Participants in the PNET4 trial and their parents/caregivers in 7 participating anonymized countries completed standardized questionnaires in their own language on executive function, health status, behavior, health-related quality of life, and medical, educational, employment, and social information. Pre- and postoperative neurologic status and serial heights and weights were also recorded. Results Data were provided by 151 of 244 eligible survivors (62%) at a median age at assessment of 15.2 years and median interval from diagnosis of 5.8 years. Compared with standard radiation therapy, hyperfractionated radiation therapy was associated with lower (ie, better) z-scores for executive function in all participants (mean intergroup difference 0.48 SDs, 95% confidence interval 0.16-0.81, P=.004), but health status, behavioral difficulties, and health-related quality of life z-scores were similar in the 2 treatment arms. Data on hearing impairment were equivocal. Hyperfractionated radiation therapy was also associated with greater decrement in height z-scores (mean intergroup difference 0.43 SDs, 95% confidence interval 0.10-0.76, P=.011). Conclusions Hyperfractionated radiation therapy was associated with better executive function and worse growth but without accompanying change in health status, behavior, or quality of life.

AB - Purpose To compare quality of survival in "standard-risk" medulloblastoma after hyperfractionated radiation therapy of the central nervous system with that after standard radiation therapy, combined with a chemotherapy regimen common to both treatment arms, in the PNET4 randomised controlled trial. Methods and Materials Participants in the PNET4 trial and their parents/caregivers in 7 participating anonymized countries completed standardized questionnaires in their own language on executive function, health status, behavior, health-related quality of life, and medical, educational, employment, and social information. Pre- and postoperative neurologic status and serial heights and weights were also recorded. Results Data were provided by 151 of 244 eligible survivors (62%) at a median age at assessment of 15.2 years and median interval from diagnosis of 5.8 years. Compared with standard radiation therapy, hyperfractionated radiation therapy was associated with lower (ie, better) z-scores for executive function in all participants (mean intergroup difference 0.48 SDs, 95% confidence interval 0.16-0.81, P=.004), but health status, behavioral difficulties, and health-related quality of life z-scores were similar in the 2 treatment arms. Data on hearing impairment were equivocal. Hyperfractionated radiation therapy was also associated with greater decrement in height z-scores (mean intergroup difference 0.43 SDs, 95% confidence interval 0.10-0.76, P=.011). Conclusions Hyperfractionated radiation therapy was associated with better executive function and worse growth but without accompanying change in health status, behavior, or quality of life.

UR - http://www.scopus.com/inward/record.url?scp=84891869161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891869161&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2013.09.046

DO - 10.1016/j.ijrobp.2013.09.046

M3 - Article

C2 - 24239386

AN - SCOPUS:84891869161

VL - 88

SP - 292

EP - 300

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -